Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 14/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.35 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.35 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.35 |
| ▸ | SLC34A1 | Q06495 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10008965 | 0.91 | MAPK1 (0.42) | MAPK1GSK3BKCNJ6KCNJ5KCNJ3 | |
| SCHEMBL10009969 | 0.85 | MAPK1 (0.43) | MAPK1 | |
| SCHEMBL10010156 | 0.85 | SLC2A1 (0.44) | MAPK1GSK3BMAPT | |
| SCHEMBL10009120 | 0.83 | MAPK1 (0.40) | MAPK1SLC34A1MAPT | |
| SCHEMBL1506344 | 0.82 | MAPK1 (0.36) | MAPK1GSK3BKCNJ6KCNJ5KCNJ3 | |
| SCHEMBL10009645 | 0.82 | MAPK1 (0.41) | MAPK1SLC34A1 | |
| SCHEMBL10010435 | 0.81 | KDR (0.41) | MAPK1GSK3BKDM4EMAPT | |
| SCHEMBL1506106 | 0.81 | MAPK1 (0.36) | MAPK1GSK3BKCNJ6KCNJ5KCNJ3 | |
| SCHEMBL10315974 | 0.79 | MAPK1 (0.46) | MAPK1MAPT | |
| SCHEMBL1506198 | 0.79 | MAPK1 (0.38) | MAPK1GSK3BKCNJ6KCNJ5KCNJ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791144-B2 | Substituted N-phenyl-1-(4-Pyridinyl)-1H-pyrazol-3-amines | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-29 | — | — | US | disclosed |
| EP-2491024-B1 | SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-20 | — | — | EP | disclosed |
| US-20120172354-A1 | Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines | JANSSEN PHARMACEUTICA NV (BE) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172354-A1 | Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines | CHRM1, CHRNA1, CHRM3 | MAPK1 1404/4885GSK3B 1943/4885KCNJ6 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.